Lassa fever medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 5: Line 5:
{{SK}} Lassa hemorrhagic fever; LHF
{{SK}} Lassa hemorrhagic fever; LHF
==Overview==
==Overview==
[[Ribavirin]], an antiviral drug, has been used with success in Lassa fever patients. It has been shown to be most effective when given early in the course of the illness. Patients should also receive supportive care consisting of maintenance of appropriate [[fluid]] and [[electrolyte]] balance, oxygenation and [[blood pressure]], as well as treatment of any other complicating [[infection]]s.<ref name=cdc>Lassa Fever:Treatment. Centers for Disease Control and Prevention. [http://www.cdc.gov/vhf/lassa/treatment/index.html Accessed on June 09, 2015].</ref>
[[Ribavirin]] is an antiviral drug that is indicated for the treatment of Lassa fever. The efficacy of ribavirin is most strongly observed when it is administered intravenously early in the course of the disease. In addition to antiviral therapy, patients should typically receive supportive care to adequately maintain respiratory status and [[fluid]] and [[electrolyte]] balance.


==Medical Therapy==
==Medical Therapy==
* All persons suspected of Lassa fever infection should be admitted to [[Isolation (health care)|isolation]] facilities and their [[body fluids]] and [[excretion|excreta]] properly disposed of.<ref name=cdc></ref>
* All hospitalized individuals with suspected Lassa fever should be isolated with proper disposal of [[body fluids]] and [[excretion|excreta]].<ref name="cdc" />
* The antiviral drug ribavirin seems to be an effective treatment for Lassa fever if given early on in the course of clinical illness<ref name=who>Fact sheet N°179: Lassa Fever. World Health Organization. [http://www.who.int/mediacentre/factsheets/fs179/en/ Accessed on June 09, 2015.] </ref>. Ribavirin is almost twice as [[effective dose|effective]] when administered [[intravenous]]ly compared to orally .<ref>{{cite journal |author=Fisher-Hoch SP, McCormick JB |title=Lassa fever vaccine |journal=Expert review of vaccines |volume=3 |issue=2 |pages=189-97 |year=2004 |pmid=15056044 |doi=10.1586/14760584.3.4.S189}}</ref> Ribavirin is a [[prodrug]] which appears to interfere with [[viral replication]] by inhibiting [[RNA]]-dependent [[DNA Replication|nucleic acid synthesis]], although the precise [[mechanism of action]] is controversial.<ref>{{cite journal |author=Crotty S, Cameron C, Andino R |title=Ribavirin's antiviral mechanism of action: lethal mutagenesis? |journal=J. Mol. Med. |volume=80 |issue=2 |pages=86-95 |year=2002 |pmid=11907645 |doi=10.1007/s00109-001-0308-0}}</ref> [[Fluid replacement]] and [[blood transfusions]] may also be required.
* Supportive care, including adequate f[[Fluid replacement|luid]] and electrolyte replacement and [[blood transfusions]], may also be required.
* [[Ribavirin]] is an antiviral drug that is indicated for the treatment of Lassa fever. The efficacy of ribavirin is most strongly observed when it is administered intravenously early in the course of the disease.<ref name="who">Fact sheet N°179: Lassa Fever. World Health Organization. [http://www.who.int/mediacentre/factsheets/fs179/en/ Accessed on June 09, 2015.] </ref> Compared with oral ribavirin, intravenous (IV) ribavirin is almost twice as [[effective dose|effective]].<ref>{{cite journal |author=Fisher-Hoch SP, McCormick JB |title=Lassa fever vaccine |journal=Expert review of vaccines |volume=3 |issue=2 |pages=189-97 |year=2004 |pmid=15056044 |doi=10.1586/14760584.3.4.S189}}</ref>  
<center>
<center>
{| style="border: 0px; font-size: 90%; margin: 3px;" align=center
{| style="border: 0px; font-size: 90%; margin: 3px;" align="center"
|-
|-
|align="center" style="background:#4479BA; padding: 3px;"|{{fontcolor|#FFF|'''Optimal Treatment'''}}
| align="center" style="background:#4479BA; padding: 3px;" |{{fontcolor|#FFF|'''Optimal Treatment'''}}
|-  
|-
|align="left" style="background:#efefef; padding: 10px;"|'''Ribavarin'''<ref name="pmid11988060">{{cite journal| author=Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB et al.| title=Hemorrhagic fever viruses as biological weapons: medical and public health management. | journal=JAMA | year= 2002 | volume= 287 | issue= 18 | pages= 2391-405 | pmid=11988060 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11988060  }} </ref>
| align="left" style="background:#efefef; padding: 10px;" |'''Ribavarin'''<ref name="pmid11988060">{{cite journal| author=Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB et al.| title=Hemorrhagic fever viruses as biological weapons: medical and public health management. | journal=JAMA | year= 2002 | volume= 287 | issue= 18 | pages= 2391-405 | pmid=11988060 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11988060  }} </ref>
*{{fontcolor|#4479BA|''Loading dose:''}} 30 mg/kg (max. 2g) IV<br>
*{{fontcolor|#4479BA|''Loading dose:''}} 30 mg/kg (max. 2g) IV<br>
*{{fontcolor|#4479BA|''Concentration dose:''}} 16 mg/kg (max. 1g) IV Q6H X 4 days, then 8 mg/kg (max. 500mg) IV Q8H X 6 days
*{{fontcolor|#4479BA|''Concentration dose:''}} 16 mg/kg (max. 1g) IV Q6H X 4 days, then 8 mg/kg (max. 500mg) IV Q8H X 6 days
|-  
|-
|}
|}
</center>
</center>


==Special Patients==
==Pregnancy==
* When Lassa fever infects [[pregnant]] women late in their [[third trimester]], the risk of death is very high (odds ratio for death 5.57). Among these patients, emergent evacuation of the uterus (by induction or surgically) has been demonstrated to decrease the risk of death.<ref>{{cite journal |author=Price ME, Fisher-Hoch SP, Craven RB, McCormick JB |title=A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy |journal=BMJ |volume=297 |issue=6648 |pages=584–7 |year=1988 |pmid=3139220 |url=http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=3139220}}</ref>  It is hypothesized that evacuating the uterus decreases the viral load significantly as the virus has high affinity for the [[placenta]] and other highly [[vascular]] tissues.  Observational studies have demonstrated that the [[fetus]] has only a one in ten chance of survival irrespective of the therapies used or the interventions attempted. For that reason, the main focus is on reducing the risk of death in the mother. Following active obstetrical intervention, treatment with ribavirin should be initiated immediately.
* For 3rd-term pregnant women with Lassa fever, the risk of death is very high (odds ratio for death 5.57). Among these patients, emergent evacuation of the uterus (by induction or surgically) has been demonstrated to decrease the risk of death.<ref>{{cite journal |author=Price ME, Fisher-Hoch SP, Craven RB, McCormick JB |title=A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy |journal=BMJ |volume=297 |issue=6648 |pages=584–7 |year=1988 |pmid=3139220 |url=http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=3139220}}</ref>  It is hypothesized that evacuating the uterus decreases the viral load significantly as the virus has high affinity for the [[placenta]] and other highly [[vascular]] tissues.  Observational studies have demonstrated that the [[fetus]] has only a one in ten chance of survival irrespective of the therapies used or the interventions attempted. For that reason, the main focus is on reducing the risk of death in the mother. Following active obstetrical intervention, treatment with ribavirin should be initiated immediately.


==References==
==References==

Revision as of 14:30, 10 June 2015

Lassa fever Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Lassa fever from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Lassa fever medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Lassa fever medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Lassa fever medical therapy

CDC on Lassa fever medical therapy

Lassa fever medical therapy in the news

Blogs on Lassa fever medical therapy

Directions to Hospitals Treating Lassa fever

Risk calculators and risk factors for Lassa fever medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Yazan Daaboul, M.D.Serge Korjian M.D.Ammu Susheela, M.D. [2]

Synonyms and keywords: Lassa hemorrhagic fever; LHF

Overview

Ribavirin is an antiviral drug that is indicated for the treatment of Lassa fever. The efficacy of ribavirin is most strongly observed when it is administered intravenously early in the course of the disease. In addition to antiviral therapy, patients should typically receive supportive care to adequately maintain respiratory status and fluid and electrolyte balance.

Medical Therapy

  • All hospitalized individuals with suspected Lassa fever should be isolated with proper disposal of body fluids and excreta.[1]
  • Supportive care, including adequate fluid and electrolyte replacement and blood transfusions, may also be required.
  • Ribavirin is an antiviral drug that is indicated for the treatment of Lassa fever. The efficacy of ribavirin is most strongly observed when it is administered intravenously early in the course of the disease.[2] Compared with oral ribavirin, intravenous (IV) ribavirin is almost twice as effective.[3]
Optimal Treatment
Ribavarin[4]
  • Loading dose: 30 mg/kg (max. 2g) IV
  • Concentration dose: 16 mg/kg (max. 1g) IV Q6H X 4 days, then 8 mg/kg (max. 500mg) IV Q8H X 6 days

Pregnancy

  • For 3rd-term pregnant women with Lassa fever, the risk of death is very high (odds ratio for death 5.57). Among these patients, emergent evacuation of the uterus (by induction or surgically) has been demonstrated to decrease the risk of death.[5] It is hypothesized that evacuating the uterus decreases the viral load significantly as the virus has high affinity for the placenta and other highly vascular tissues. Observational studies have demonstrated that the fetus has only a one in ten chance of survival irrespective of the therapies used or the interventions attempted. For that reason, the main focus is on reducing the risk of death in the mother. Following active obstetrical intervention, treatment with ribavirin should be initiated immediately.

References

  1. Fact sheet N°179: Lassa Fever. World Health Organization. Accessed on June 09, 2015.
  2. Fisher-Hoch SP, McCormick JB (2004). "Lassa fever vaccine". Expert review of vaccines. 3 (2): 189–97. doi:10.1586/14760584.3.4.S189. PMID 15056044.
  3. Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB; et al. (2002). "Hemorrhagic fever viruses as biological weapons: medical and public health management". JAMA. 287 (18): 2391–405. PMID 11988060.
  4. Price ME, Fisher-Hoch SP, Craven RB, McCormick JB (1988). "A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy". BMJ. 297 (6648): 584–7. PMID 3139220.


Template:WikiDoc Sources